-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cetuximab Biosimilar in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cetuximab Biosimilar in Ovarian Cancer Drug Details: Cetuximab biosimilar (CDP-1) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olokizumab in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olokizumab in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Olokizumab in Rheumatoid Arthritis Drug Details: Olokizumab (Artlegia) is a humanized monoclonal antibody....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NLG-207 in Epithelial Ovarian Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NLG-207 in Epithelial Ovarian Cancer Drug Details: NLG-207 (CRLX-101) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Romosozumab in Osteoporosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Romosozumab in Osteoporosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Romosozumab in OsteoporosisDrug Details: Romosozumab (Evenity) is a humanized monoclonal antibody. It is formulated...
-
Company Profile
Sitecore Corp AS – Company Profile
Sitecore Corp AS (Sitecore), a subsidiary of Sitecore Holding II AS, is a provider of management software and web context marketing platform solutions. The company offers content cloud, engagement cloud and commerce cloud platform products. Its major offerings include Content Hub One, XM Cloud, Digital Experience Platform (DXP), Sitecore CDP and OrderCloud. Sitecore’s solution portfolio comprises personalization and testing, marketing automation, order management, customer data management, content management, search and merchandising, digital asset management, content operations, storefront and marketplaces. It...
Add to Basket -
Product Insights
CDP – Lake House Development – California
Equip yourself with the essential tools needed to make informed and profitable decisions with our CDP - Lake House Development - California report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the CDP...
-
Product Insights
CDP/ Eni Plenitude – Sardegna Sud Occidentale Offshore Wind Farm 500 MW – Sardinia
Equip yourself with the essential tools needed to make informed and profitable decisions with our CDP/ Eni Plenitude - Sardegna Sud Occidentale Offshore Wind Farm 500 MW - Sardinia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the...
-
Product Insights
CDP – Piazza Verdi Redevelopment – Latium
Equip yourself with the essential tools needed to make informed and profitable decisions with our CDP - Piazza Verdi Redevelopment - Latium report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the CDP...
-
Product Insights
CDP – The Avenue Hyatt Centric Hotel – Texas
Equip yourself with the essential tools needed to make informed and profitable decisions with our CDP - The Avenue Hyatt Centric Hotel - Texas report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
CDP/ CIP/ Eni Plenitude – Olbia Offshore Wind Farms 1500 MW – Sardinia
Equip yourself with the essential tools needed to make informed and profitable decisions with our CDP/ CIP/ Eni Plenitude - Olbia Offshore Wind Farms 1500 MW - Sardinia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full...